JP2005534330A - アルブミン融合繊毛様神経栄養因子 - Google Patents
アルブミン融合繊毛様神経栄養因子 Download PDFInfo
- Publication number
- JP2005534330A JP2005534330A JP2004526896A JP2004526896A JP2005534330A JP 2005534330 A JP2005534330 A JP 2005534330A JP 2004526896 A JP2004526896 A JP 2004526896A JP 2004526896 A JP2004526896 A JP 2004526896A JP 2005534330 A JP2005534330 A JP 2005534330A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- albumin
- biologically active
- active peptide
- cntf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 130
- 108010088751 Albumins Proteins 0.000 title claims abstract description 130
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 title claims abstract description 113
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 title claims abstract description 112
- 230000004927 fusion Effects 0.000 title claims description 56
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 73
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 73
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 239000012634 fragment Substances 0.000 claims abstract description 46
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 102000005962 receptors Human genes 0.000 claims abstract description 10
- 108020003175 receptors Proteins 0.000 claims abstract description 10
- 108010014210 axokine Proteins 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 208000008589 Obesity Diseases 0.000 claims description 13
- 235000020824 obesity Nutrition 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 230000008499 blood brain barrier function Effects 0.000 claims description 8
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 7
- 206010028813 Nausea Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 210000005260 human cell Anatomy 0.000 claims 3
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 claims 2
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 101710153593 Albumin A Proteins 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 61
- 108091006905 Human Serum Albumin Proteins 0.000 description 61
- 210000004899 c-terminal region Anatomy 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 32
- 150000001413 amino acids Chemical group 0.000 description 32
- 238000012360 testing method Methods 0.000 description 32
- 230000001225 therapeutic effect Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 27
- 239000000902 placebo Substances 0.000 description 27
- 229940068196 placebo Drugs 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 24
- 230000037396 body weight Effects 0.000 description 24
- 230000004580 weight loss Effects 0.000 description 18
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 102000016267 Leptin Human genes 0.000 description 15
- 108010092277 Leptin Proteins 0.000 description 15
- 229940039781 leptin Drugs 0.000 description 15
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 238000007920 subcutaneous administration Methods 0.000 description 14
- 238000003860 storage Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 102000007562 Serum Albumin Human genes 0.000 description 11
- 108010071390 Serum Albumin Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012466 permeate Substances 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000010254 subcutaneous injection Methods 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 102100029727 Enteropeptidase Human genes 0.000 description 3
- 108010013369 Enteropeptidase Proteins 0.000 description 3
- 206010022095 Injection Site reaction Diseases 0.000 description 3
- 101710151321 Melanostatin Proteins 0.000 description 3
- 102400000064 Neuropeptide Y Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 235000000891 standard diet Nutrition 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 238000001134 F-test Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000993364 Homo sapiens Ciliary neurotrophic factor Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 2
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000019439 energy homeostasis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013230 female C57BL/6J mice Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000054930 Agouti-Related Human genes 0.000 description 1
- 108700021677 Agouti-Related Proteins 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- URAUIUGLHBRPMF-NAKRPEOUSA-N Arg-Ser-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O URAUIUGLHBRPMF-NAKRPEOUSA-N 0.000 description 1
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- UOAVQQRILDGZEN-SRVKXCTJSA-N His-Asp-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UOAVQQRILDGZEN-SRVKXCTJSA-N 0.000 description 1
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 1
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- ZDSNOSQHMJBRQN-SRVKXCTJSA-N Leu-Asp-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ZDSNOSQHMJBRQN-SRVKXCTJSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108010075563 No. 407 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- STKZKWFOKOCSLW-UMPQAUOISA-N Trp-Thr-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)O)=CNC2=C1 STKZKWFOKOCSLW-UMPQAUOISA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 208000027909 hemorrhagic diarrhea Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003796 lateral hypothalamic area Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220217079 rs144996870 Human genes 0.000 description 1
- 102200015136 rs398122975 Human genes 0.000 description 1
- 102220141930 rs778259023 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40183302P | 2002-08-07 | 2002-08-07 | |
| PCT/EP2003/008710 WO2004015113A2 (en) | 2002-08-07 | 2003-08-06 | Albumin-fused ciliary neurotrophic factor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010089560A Division JP2010213707A (ja) | 2002-08-07 | 2010-04-08 | アルブミン融合繊毛様神経栄養因子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005534330A true JP2005534330A (ja) | 2005-11-17 |
| JP2005534330A5 JP2005534330A5 (enExample) | 2006-08-24 |
Family
ID=31715745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004526896A Pending JP2005534330A (ja) | 2002-08-07 | 2003-08-06 | アルブミン融合繊毛様神経栄養因子 |
| JP2010089560A Withdrawn JP2010213707A (ja) | 2002-08-07 | 2010-04-08 | アルブミン融合繊毛様神経栄養因子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010089560A Withdrawn JP2010213707A (ja) | 2002-08-07 | 2010-04-08 | アルブミン融合繊毛様神経栄養因子 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1529108A2 (enExample) |
| JP (2) | JP2005534330A (enExample) |
| KR (1) | KR20050065519A (enExample) |
| AU (1) | AU2003271043A1 (enExample) |
| CA (1) | CA2496002A1 (enExample) |
| WO (1) | WO2004015113A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
| US9057061B2 (en) | 2003-12-23 | 2015-06-16 | Novozymes Biopharma Dk A/S | Gene expression technique |
| GB0329722D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
| CN102462662A (zh) * | 2010-08-16 | 2012-05-23 | 重庆富进生物医药有限公司 | 脂质体包裹重组人睫状神经营养因子 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000502901A (ja) * | 1995-12-30 | 2000-03-14 | デルタ、バイオテクノロジー、リミテッド | 成長ホルモンおよび血清アルブミンに対する組換え融合タンパク質 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719593B1 (fr) * | 1994-05-06 | 1996-05-31 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant. |
| US6926898B2 (en) * | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2286128T3 (es) * | 2000-06-30 | 2007-12-01 | Zymogenetics, Inc. | Proteina zcyto21 tipo interferon. |
-
2003
- 2003-08-06 WO PCT/EP2003/008710 patent/WO2004015113A2/en not_active Ceased
- 2003-08-06 CA CA002496002A patent/CA2496002A1/en not_active Abandoned
- 2003-08-06 AU AU2003271043A patent/AU2003271043A1/en not_active Abandoned
- 2003-08-06 JP JP2004526896A patent/JP2005534330A/ja active Pending
- 2003-08-06 EP EP03750409A patent/EP1529108A2/en not_active Ceased
- 2003-08-06 KR KR1020057002155A patent/KR20050065519A/ko not_active Ceased
-
2010
- 2010-04-08 JP JP2010089560A patent/JP2010213707A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000502901A (ja) * | 1995-12-30 | 2000-03-14 | デルタ、バイオテクノロジー、リミテッド | 成長ホルモンおよび血清アルブミンに対する組換え融合タンパク質 |
Non-Patent Citations (5)
| Title |
|---|
| EUR. J. BIOCHEM., vol. 231, JPN6009021147, 1995, pages 563 - 569, ISSN: 0001313675 * |
| INT. J. OBES., vol. 24, no. 1, JPN6009021142, 2000, pages 102 - 328, ISSN: 0001313677 * |
| INT. J. OBES., vol. 25, no. 2, JPN6009021149, 2001, pages 111 - 291, ISSN: 0001313674 * |
| PROC. NATL. ACAD. SCI. USA., vol. 89, JPN6009021145, 1992, pages 1904 - 1908, ISSN: 0001313676 * |
| PROC. NATL. ACAD. SCI. USA., vol. 98, no. 8, JPN6009021143, 2001, pages 4652 - 4657, ISSN: 0001313678 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050065519A (ko) | 2005-06-29 |
| WO2004015113A2 (en) | 2004-02-19 |
| EP1529108A2 (en) | 2005-05-11 |
| AU2003271043A1 (en) | 2004-02-25 |
| CA2496002A1 (en) | 2004-02-19 |
| WO2004015113A3 (en) | 2004-05-06 |
| JP2010213707A (ja) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6059802B2 (ja) | 長時間作用型ｇｌｐ−１ペプチドの使用 | |
| CN102197049B (zh) | 胰岛淀粉样多肽衍生物 | |
| CN103649115B (zh) | 多肽 | |
| JP6704358B2 (ja) | 代謝障害を治療するための組成物および使用方法 | |
| EP2376520B1 (en) | Insulin analogs | |
| KR20120036947A (ko) | 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법 | |
| US20080293638A1 (en) | Albumin-fused ciliary neurotrophic factor | |
| KR20150124955A (ko) | 사람 성장 호르몬 유사체를 사용한 소아 성장 호르몬 결핍증의 치료 방법 | |
| AU2003200839A1 (en) | Extended glucagon-like peptide-1 analogs | |
| JP2007504178A (ja) | 安定なペプチドの製剤 | |
| JP2016519130A (ja) | 治療ペプチド | |
| JP2010528092A (ja) | 代謝疾患の治療における治療剤としての非アシル化グレリン | |
| CN116322739A (zh) | Glp-1r激动剂/fgf21融合蛋白 | |
| KR102696075B1 (ko) | 고혈당증의 치료 및 예방을 위한 펩타이드 | |
| US20190276510A1 (en) | Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia | |
| US10689430B2 (en) | Insulin receptor partial agonists | |
| JP2010213707A (ja) | アルブミン融合繊毛様神経栄養因子 | |
| JP6948331B2 (ja) | Ｇｄｆ１１での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する | |
| KR20150110677A (ko) | N 말단 절단된 인슐린 유사체 | |
| US20070218504A1 (en) | Human leptin-derived polypeptides and uses thereof | |
| CN116113639A (zh) | 活性降低的glp-1r激动肽 | |
| CN114144426A (zh) | 餐时或基础胰岛素类似物通过内部二硒桥的稳定化 | |
| US9314506B2 (en) | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors | |
| WO2025087301A1 (en) | Circular rna encoding glp-1 and the use thereof | |
| EP3720467B1 (en) | Methods for treatment of neuropathic pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060703 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090508 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090806 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091109 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100524 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100723 |